This is a profile image of Alex Devereson

Alex Devereson


Helps pharmaceutical companies and investors leverage digital and analytics to improve patient outcomes and drive innovation and growth

Alex advises pharmaceutical and biotech companies on how to maximize the value of digital and analytics across the value chain, and supports clients across strategy, organization, analytics delivery, capability building, and change management. He has deep expertise in leveraging advanced analytics in real-world evidence generation, and has experience in unlocking innovation in research, accelerating clinical development, and optimizing commercial activities. Throughout his work, Alex focuses on helping companies enhance their understanding of disease biology and clinical outcomes to maximize patient benefit.

Alex also serves investors on a range of healthcare topics across the investment lifecycle, often helping them to assess value creation in the tech-enabled healthcare services space.

Recent examples of his work include:

  • leading a multiyear analytics transformation with QuantumBlack for a leading pharmaceutical company, from vision and strategy to execution of more than ten use cases across the value chain
  • leveraging machine learning approaches to novel insights on real world data resulting in scientific publications, and reshaping of asset, franchise, and lifecycle management strategies
  • developing integrated evidence generation strategies for multiple global pharmaceutical companies
  • defining enterprise corporate strategy, digital strategy, and medical affairs strategy for a mid-cap pharmaceutical company
  • advising on asset strategy for several major blockbuster therapies across oncology, immunology, rare diseases, neurology, and primary care conditions
  • leading over 15 commercial due diligence, exit preparation, and portfolio strategy projects for healthcare technology companies

Before joining McKinsey, Alex wrote his PhD thesis on mRNA localization in development, and has published in peer-reviewed journals.

Published Work

Quarterly value releases: Transforming pharma through digital and analytics—fast,” McKinsey & Company, December 2022

How AI could revolutionize drug discovery,” McKinsey & Company, November 2022

How AI can accelerate R&D for cell and gene therapies,” McKinsey & Company, November 2022

AI in biopharma research: A time to focus and scale,” McKinsey & Company, October 2022

Generating real-world evidence at scale using advanced analytics,” McKinsey & Company, March 2022

The UK biotech sector: The path to global leadership,” McKinsey & Company, December 2021

Ten battlegrounds for digital and analytics in life sciences,” McKinsey & Company, August 2020

Creating value from next-generation real-world evidence,” McKinsey & Company, July 2020

Private equity opportunities in healthcare tech,” McKinsey & Company, May 2019


University of Oxford, Christ Church
PhD, chromosome and developmental biology

University College London
BSc, biology